Tinaghanao, Addi .
HRN: 26-72-52 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/18/2025
CO-AMOXICLAV 625MG (TAB)
02/18/2025
02/24/2025
PO
625mg
Once Daily
Tonsillopharyngitis
Waiting Final Action
Indication: Empiric Type of Infection: Eye, Ear, Nose, Throat, & Mouth Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes